NASDAQ:COLL Collegium Pharmaceutical - COLL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $28.08 +0.70 (+2.56%) (As of 01/31/2023 05:19 PM ET) Add Compare Share Share Today's Range$27.09▼$28.4050-Day Range$21.25▼$28.7452-Week Range$14.04▼$30.22Volume278,604 shsAverage Volume467,745 shsMarket Capitalization$942.70 millionP/E RatioN/ADividend YieldN/APrice Target$33.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Collegium Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside17.2% Upside$33.00 Price TargetShort InterestBearish12.25% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment0.36Based on 13 Articles This WeekInsider TradingSelling Shares$4.38 M Sold Last QuarterProj. Earnings Growth54.12%From $3.64 to $5.61 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector659th out of 1,055 stocksPharmaceutical Preparations Industry337th out of 518 stocks 2.4 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.00, Collegium Pharmaceutical has a forecasted upside of 17.2% from its current price of $28.16.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.25% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently increased by 8.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 3.0 News and Social Media Coverage News SentimentCollegium Pharmaceutical has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Collegium Pharmaceutical this week, compared to 2 articles on an average week.Search Interest7 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows6 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,377,640.00 in company stock.Percentage Held by InsidersOnly 4.34% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 54.12% in the coming year, from $3.64 to $5.61 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is -22.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is -22.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCollegium Pharmaceutical has a PEG Ratio of 0.25. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 4.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Collegium Pharmaceutical (NASDAQ:COLL) StockCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Stock News HeadlinesJanuary 29, 2023 | seekingalpha.comCollegium Pharmaceutical: Low Multiples Justified, Growth To Come At A CostJanuary 28, 2023 | finance.yahoo.comCollegium Pharmaceutical's (NASDAQ:COLL) investors will be pleased with their decent 62% return over the last yearJanuary 31, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 28, 2023 | americanbankingnews.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Forecasted to Earn FY2023 Earnings of $7.55 Per ShareJanuary 25, 2023 | americanbankingnews.comQ4 2022 EPS Estimates for Collegium Pharmaceutical, Inc. Decreased by Analyst (NASDAQ:COLL)January 13, 2023 | marketwatch.comPainful Diabetic Neuropathy Drug Market 2023 : Regional Scope, Growth Statistics, Demand and Regional Outlook 2029January 11, 2023 | finance.yahoo.comCOLL vs. ZTS: Which Stock Is the Better Value Option?January 4, 2023 | marketwatch.comCollegium Pharmaceutical Shares Gain 11% on 2023 Guidance, OutlookJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 4, 2023 | msn.comCollegium gains on 2023 financial guidance, $100M share buybacksJanuary 3, 2023 | marketwatch.comAllergy Treatment Market 2023 : Trend Analysis, Competitive Outlook of Top Industry Players and Future Expansion by 2028January 3, 2023 | benzinga.comMike Heffernan appointed Chairman of NMD Pharma's Board of DirectorsDecember 22, 2022 | finance.yahoo.comAppeals Court Affirms Validity of Collegium’s Belbuca® PatentsNovember 22, 2022 | finance.yahoo.comCollegium to Participate in Piper Sandler 34th Annual Healthcare ConferenceNovember 8, 2022 | finance.yahoo.comCollegium Pharmaceutical Third Quarter 2022 Earnings: EPS Beats ExpectationsNovember 3, 2022 | finance.yahoo.comCollegium Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comCollegium Pharmaceutical (COLL) Lags Q3 Earnings EstimatesOctober 25, 2022 | nasdaq.comInvesting in Collegium Pharmaceutical (NASDAQ:COLL) five years ago would have delivered you a 76% gainOctober 20, 2022 | finance.yahoo.comCollegium to Report Third Quarter 2022 Financial Results on November 3, 2022October 11, 2022 | uk.finance.yahoo.comCollegium Pharmaceutical, Inc. (COLL)August 30, 2022 | finance.yahoo.comCollegium Announces 11 Poster Presentations at PAINWeek 2022 National ConferenceAugust 8, 2022 | finance.yahoo.comAnalyst Sees This 'Specialty Pharma' Stock Stuck Until Prescription Trends ImproveAugust 5, 2022 | seekingalpha.comCollegium Pharmaceutical Q2 2022 Earnings PreviewAugust 4, 2022 | finance.yahoo.comCollegium Reports Second Quarter 2022 Financial ResultsJuly 30, 2022 | morningstar.comCollegium Pharmaceutical Inc Stock Quote COLLJuly 21, 2022 | finance.yahoo.comCollegium to Report Second Quarter 2022 Financial Results on August 4, 2022July 6, 2022 | finance.yahoo.comIs the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Company Calendar Last Earnings11/03/2022Today1/31/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Forecast$33.00 High Stock Price Forecast$42.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+17.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E Ratio7.71 P/E Growth0.25Net Income$71.52 million Net Margins-11.84% Pretax Margin-16.57% Return on Equity12.66% Return on Assets2.29% Debt Debt-to-Equity Ratio2.95 Current Ratio0.98 Quick Ratio0.82 Sales & Book Value Annual Sales$361.68 million Price / Sales2.61 Cash Flow$2.24 per share Price / Cash Flow12.56 Book Value$5.87 per share Price / Book4.78Miscellaneous Outstanding Shares33,572,000Free Float32,115,000Market Cap$942.70 million OptionableOptionable Beta0.82 Key ExecutivesMr. Michael Thomas Heffernan B.S. Pharm (Age 59)R.Ph., Co-Founder & Chairman Comp: $110kMr. Joseph J. Ciaffoni (Age 52)Pres, CEO & Director Comp: $1.1MMs. Colleen Tupper (Age 47)Exec. VP & CFO Comp: $631.24kMs. Shirley R. Kuhlmann (Age 39)Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. Comp: $620.1kMr. Scott Dreyer (Age 50)Exec. VP & Chief Commercial Officer Comp: $591kDr. Richard Malamut M.D. (Age 63)Exec. VP & Chief Medical Officer Comp: $612.2kMs. Alex DasallaHead of Investor RelationsMr. Bart J. DunnExec. VP of Strategy & Corp. Devel.Ms. Marlo ManningHead of HRMr. Scott SudduthHead of Technical OperationsMore ExecutivesKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSAIGM BiosciencesNASDAQ:IGMSGemini TherapeuticsNASDAQ:GMTXKura OncologyNASDAQ:KURAAmryt PharmaNASDAQ:AMYTView All CompetitorsInsiders & InstitutionsSummit Global InvestmentsBought 367 shares on 1/31/2023Ownership: 0.293%New York State Common Retirement FundSold 30,890 shares on 1/30/2023Ownership: 0.075%Comerica BankSold 6,229 shares on 1/26/2023Ownership: 0.059%Louisiana State Employees Retirement SystemSold 400 shares on 1/24/2023Ownership: 0.047%Eastern BankBought 9,335 shares on 1/24/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions COLL Stock - Frequently Asked Questions Should I buy or sell Collegium Pharmaceutical stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COLL shares. View COLL analyst ratings or view top-rated stocks. What is Collegium Pharmaceutical's stock price forecast for 2023? 4 equities research analysts have issued 12 month price objectives for Collegium Pharmaceutical's stock. Their COLL share price forecasts range from $26.00 to $42.00. On average, they predict the company's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price. View analysts price targets for COLL or view top-rated stocks among Wall Street analysts. How have COLL shares performed in 2023? Collegium Pharmaceutical's stock was trading at $23.20 at the start of the year. Since then, COLL stock has increased by 18.0% and is now trading at $27.38. View the best growth stocks for 2023 here. Are investors shorting Collegium Pharmaceutical? Collegium Pharmaceutical saw a increase in short interest in January. As of January 15th, there was short interest totaling 3,970,000 shares, an increase of 8.5% from the December 31st total of 3,660,000 shares. Based on an average daily volume of 306,100 shares, the days-to-cover ratio is currently 13.0 days. Approximately 12.3% of the shares of the stock are sold short. View Collegium Pharmaceutical's Short Interest. When is Collegium Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our COLL earnings forecast. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its quarterly earnings data on Thursday, November, 3rd. The specialty pharmaceutical company reported $0.96 EPS for the quarter, missing analysts' consensus estimates of $1.04 by $0.08. The specialty pharmaceutical company earned $127.01 million during the quarter, compared to the consensus estimate of $123.65 million. Collegium Pharmaceutical had a negative net margin of 11.84% and a positive trailing twelve-month return on equity of 12.66%. What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical updated its FY 2023 earnings guidance on Wednesday, January, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $550.58 million. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH). When did Collegium Pharmaceutical IPO? (COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. What is Collegium Pharmaceutical's stock symbol? Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL." Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.61%), Assenagon Asset Management S.A. (0.40%), Exchange Traded Concepts LLC (0.23%), Acorn Financial Advisory Services Inc. ADV (0.16%), Values First Advisors Inc. (0.14%) and New York State Common Retirement Fund (0.08%). Insiders that own company stock include Alison B Fleming, Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Collegium Pharmaceutical's stock price today? One share of COLL stock can currently be purchased for approximately $27.38. How much money does Collegium Pharmaceutical make? Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $919.15 million and generates $276.87 million in revenue each year. The specialty pharmaceutical company earns $71.52 million in net income (profit) each year or ($1.26) on an earnings per share basis. How many employees does Collegium Pharmaceutical have? The company employs 152 workers across the globe. How can I contact Collegium Pharmaceutical? Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com. This page (NASDAQ:COLL) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.